B6.129S5(Cg)- Rpl13a^tm1.1Jesc /J

Home
Services
R&D Services for Diabetes Mellitus and Diabetic Complications
Type 2 Diabetes Mellitus Research and Development Services
T2DM Modeling Service
T2DM Mouse Models
B6.129S5(Cg)- Rpl13a^tm1.1Jesc /J

Inquiry

ace

* First Name
* Last Name
* Business Email
Phone
Company/Institution
Job Title
* Services or Products of Interest (DMM-001264) B6.129S5(Cg)- Rpl13atm1.1Jesc /J
When do you expect your project to start?
Project Description
* All of our services and products are intended for preclinical research use only and cannot be used to diagnose, treat or manage patients.
* Tick to confirm the Research Use Only (RUO) statement.

B6.129S5(Cg)- Rpl13a^tm1.1Jesc /J

Inquiry

Cat. No.: DMM-001264

Status	Age	Sex
Live Mouse Frozen Embryo	4 weeks 12 weeks Customized Age	Male Female

Model Overview
Model Description	Rpl13a -snoless mice carry a targeted deletion of four intronic snoRNAs (U32a, U33, U34, and U35a). Expression of the host Rpl13a ribosomal protein gene is not perturbed.
Strain Name	B6.129S5(Cg)-Rpl13atm1.1Jesc/J
Background Strain	129S5/SvEvBrd
SPF	Yes
Research Application	Diabetes

Target Information
Target Name	Rpl13a
Synonyms	1810026N22Rik, L13A, RGD1562020, TSTA1, Tstap198-7, tum-antigen, tum-transplantation antigen P198, uL13
Gene ID	23521

All of our services and products are intended for preclinical research use only and cannot be used to diagnose, treat or manage patients.

Related Models

Ace Therapeutics has a team of experts in the field of endocrine and metabolic research, aiming to provide innovative preclinical contract research solutions to cope with diabetes and its complications. We provide customized solutions and technical support, enabling the transformation of promising concepts into innovative treatments, thus accelerating the drug development process of diabetes.

Quick Links

Contact Info

Copyright © Ace Therapeutics. All Rights Reserved.

Top